Respiratory illness levels in the U.S. have declined so much in recent weeks that they are approaching numbers usually seen during non-flu season.
"This flu season started really early because there were so many children with zero experience with flu, common colds, and RSV," David Celentano, ScD, chair of epidemiology at Johns Hopkins Bloomberg School of Public Health, told Data are now pointing to what may amount to simply an early peak for flu and RSV. About 25 million people in the U.S. have had the flu this year and 17,000 people have died of it.
The once record-setting hospitalization rate for the flu has fizzled so much that this season may finish up below average for hospitalizations, the CDC projected. The agency said this year's flu vaccine has been very effective against circulating strains. COVID-19 metrics are also trending steeply downward, with some western parts of the U.S. reporting"some of their lowest-ever case and hospitalization rates," Despite fewer COVID-19 cases and hospitalizations nationwide, the virus remains deadly, with most January days seeing more than 500 deaths each. predicted that the XBB.1.5 variant would be circulating nationally above 50% for the first time this week.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Flu, RSV on Decline, but COVID Deaths PersistRespiratory illness levels in the U.S. have declined so much in recent weeks that they are approaching numbers usually seen during non-flu season.
Les mer »
Data: Looking at COVID-19, flu, and RSV heading into Super BowlAccording to the state health department, since January 1 there have been 10,458 COVID-19 cases recorded, 3,160 influenza cases, and 1,673 cases of RSV. MORE ⬇️
Les mer »
Managing Respiratory Symptoms in the 'Tripledemic' EraReaders weighed in on Dr Charles Vega's approach to a patient whose symptoms could be from COVID-19, flu, or RSV. Tripledemic
Les mer »
Moderna’s RSV vaccine gets Breakthrough Therapy statusModerna Inc. said Monday that the Food and Drug Administration granted the company’s experimental respiratory syncytial virus vaccine a Breakthrough Therapy...
Les mer »
FDA grants expedited review for Moderna RSV vaccine for 60 and olderModerna announced Monday that its vaccine against respiratory syncytial virus, or RSV, for adults 60 years and older has been granted breakthrough designation from the Food and Drug Administration.
Les mer »